BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36652041)

  • 21. Ophthalmological assessment of children with neurofibromatosis type 1.
    Cassiman C; Legius E; Spileers W; Casteels I
    Eur J Pediatr; 2013 Oct; 172(10):1327-33. PubMed ID: 23708214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visual evoked potentials in children with neurofibromatosis type 1.
    Iannaccone A; McCluney RA; Brewer VR; Spiegel PH; Taylor JS; Kerr NC; Pivnick EK
    Doc Ophthalmol; 2002 Jul; 105(1):63-81. PubMed ID: 12152804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials.
    Chang BC; Mirabella G; Yagev R; Banh M; Mezer E; Parkin PC; Westall CA; Buncic JR
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2895-902. PubMed ID: 17525226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More.
    Kinori M; Armarnik S; Listernick R; Charrow J; Zeid JL
    Am J Ophthalmol; 2021 Jan; 221():91-96. PubMed ID: 32283094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.
    Thiagalingam S; Flaherty M; Billson F; North K
    Ophthalmology; 2004 Mar; 111(3):568-77. PubMed ID: 15019338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Utility of Early Brain MRI for Patients with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Long-Term Follow-Up in a Tertiary Referral Hospital.
    Rony C; Aharoni S; Halevy A
    Neuropediatrics; 2022 Oct; 53(5):370-375. PubMed ID: 35381604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.
    Pinheiro SL; Maciel J; Cavaco D; Figueiredo AA; Damásio IL; Donato S; Passos J; Simões-Pereira J
    Hormones (Athens); 2023 Mar; 22(1):79-85. PubMed ID: 36269545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.
    Prada CE; Hufnagel RB; Hummel TR; Lovell AM; Hopkin RJ; Saal HM; Schorry EK
    J Pediatr; 2015 Oct; 167(4):851-856.e1. PubMed ID: 26233602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rare case of optic pathway glioma with extensive intra-ocular involvement in a child with neurofibromatosis type 1.
    Gupta V; Sabri K; Whelan KF; Viscardi V
    Middle East Afr J Ophthalmol; 2015; 22(1):117-8. PubMed ID: 25624686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of the ophthalmological examinations in neurofibromatosis type 1. Proposal for a new screening algorithm.
    Caen S; Cassiman C; Legius E; Casteels I
    Eur J Paediatr Neurol; 2015 Jul; 19(4):415-22. PubMed ID: 25797697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.
    Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S
    Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optic pathway glioma in children: 10 years of experience in a single institution.
    Doganis D; Pourtsidis A; Tsakiris K; Baka M; Kouri A; Bouhoutsou D; Varvoutsi M; Servitzoglou M; Dana H; Kosmidis H
    Pediatr Hematol Oncol; 2016 Mar; 33(2):102-8. PubMed ID: 27007263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multimodal Imaging of Choroidal Nodules in Neurofibromatosis Type I.
    Kecer F; Sharashidze A; Popová V; Bušányová B; Gerinec A; Tomčíková D
    Cesk Slov Oftalmol; 2024; 80(2):86-92. PubMed ID: 38413225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
    Listernick R; Ferner RE; Liu GT; Gutmann DH
    Ann Neurol; 2007 Mar; 61(3):189-98. PubMed ID: 17387725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas.
    Kelly JP; Leary S; Khanna P; Weiss AH
    Ophthalmology; 2012 Jun; 119(6):1231-7. PubMed ID: 22364864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of retinal nerve fiber layer thickness and ganglion cell layer-inner plexiform layer thickness in patients with optic pathway gliomas.
    Hepokur M; Sarici AM
    Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1757-1765. PubMed ID: 29754292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat.
    Azizi AA; Walker DA; Liu JF; Sehested A; Jaspan T; Pemp B; Simmons I; Ferner R; Grill J; Hargrave D; Driever PH; Evans DG; Opocher E;
    Neuro Oncol; 2021 Jan; 23(1):100-111. PubMed ID: 32628746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.
    de Blank PMK; Fisher MJ; Liu GT; Gutmann DH; Listernick R; Ferner RE; Avery RA
    J Neuroophthalmol; 2017 Sep; 37 Suppl 1(Suppl 1):S23-S32. PubMed ID: 28806346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of optic pathway glioma screening in young children with neurofibromatosis type I: questions generated by a clinical audit.
    Pilling RF; Lloyd IC; Huson S
    Eye (Lond); 2010 Oct; 24(10):1603-5. PubMed ID: 20689568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.
    Kotch C; Avery R; Getz KD; Bouffet E; de Blank P; Listernick R; Gutmann DH; Bornhorst M; Campen C; Liu GT; Aplenc R; Li Y; Fisher MJ
    Neuro Oncol; 2022 Aug; 24(8):1377-1386. PubMed ID: 35018469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.